Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
Status:
Recruiting
Trial end date:
2031-05-31
Target enrollment:
Participant gender:
Summary
This study will test polatuzumab vedotin in combination with rituximab in patients with
treatment-naïve CD20-positive post-transplant lymphoproliferative disorder (PTLD) based on
the established efficacy of polatuzumab vedotin in B-cell lymphomas and the inadequate
response rate of PTLD to single-agent rituximab. The hypothesis is that this combination
therapy will be safe, well-tolerated, and effective. If so, patients with PTLD will be able
to be spared the toxicity of anthracycline-based chemotherapy. Additionally, the role of the
tumor microenvironment and the role of anellovirus, a non-human pathogen virus, will be
explored as prognostic markers in PTLD.